BioMarin Hit With Del. Derivative Suit Over Missed Deadline
A BioMarin Pharmaceutical Inc. stockholder on Friday launched a derivative suit in Delaware's Court of Chancery, seeking a company recovery for damages caused by alleged director failures to act promptly on threats...To view the full article, register now.
Already a subscriber? Click here to view full article